|
|
|
|
The technology transfer of a monoclonal antibody drug product for late-phase clinical and commercial launch is a complex and multifaceted process. Discover strategies to manage risks, ensure regulatory compliance, and maintain product quality — accelerating time-to-market, delivering safe, effective therapies to patients.
|
|
|
|
|
Explore how strategic investments and acquisitions are transforming sterile fill/finish, prefilled syringe, and drug-device assembly capabilities. In this exclusive interview, PCI Pharma Services shares how they’re scaling innovation to deliver patient-centric injectable therapies faster, safer, and at global scale.
|
|
|
|
|
Incorporating self-administration drug-device combination products into clinical trials benefits patients and manufacturers alike. Discover how these devices offer a solution to the challenges of precise dosing, patient compliance, retention, and safety — uplifting the overall trial experience for patients and providing real world insights for sponsors.
|
|
|
|
|
|
|
Jeff Clement, Executive Director, Technical Sales Drug Product Development and Manufacturing, provides updates for 2025 on PCIs global sterile fill/finish and lyophilization capabilities, capacities, and how strategic investments in new technologies and facility acquisitions/expansions allow PCI to meet growing industry needs for expert sterile development and manufacturing solutions.
|
|
|
|
|
|
|
|
ABOUT PCI PHARMA SERVICES
|
|
|
|
|
|
|
As a world-leading CDMO, PCI offers integrated sterile manufacturing together with advanced drug delivery and drug-device final assembly, testing and packaging under one corporate roof to accelerate speed to market, reduce risk, and cut costs — helping you achieve commercial success faster.
For more information on any of the featured articles, please contact PCI Pharma Services at talkfuture@pci.com.
|
|
|
